Ｍasaki Ｋato（Kinki/Osaka）
Professor and Chair, Director of Clinical Department
In our brain screening program, we utilize brain MRI, amyloid PET, and higher-order cognitive function tests to detect dementia before clinical onset.
We provide highly specialized expertise and a comprehensive follow-up system for the diagnosis and treatment of treatment-resistant depression.
Our team possesses advanced skills and expertise to accurately diagnose and effectively manage difficult-to-treat psychiatric disorders, guiding patients toward recovery.
- Clinical department/Main areas of expertise
- Specialized area
-
- Diagnosis and Treatment of Treatment-Resistant Depression
Clinical Pharmacology: Appropriate Use of Psychotropic Medications and Monotherapy Detail
- Diagnosis and Treatment of Treatment-Resistant Depression
- Qualifications/Academia/Position
-
- Doctor of Medical Science (Ph.D. in Medicine)
- Designated Psychiatrist under the Mental Health and Welfare Act (Japan)
- 精神科専門医/指導医
- Supervising / Board-Certified Physician, Japanese Society of Clinical Neuropsychopharmacology
- Board-Certified / Supervising Psychiatrist in General Hospital Collaboration
- Certified Occupational Health Physician, Japan Medical Association
- Councilor, Japanese Society of Psychiatry and Neurology
- Councilor, Japanese Association of General Hospital Psychiatry
- Councilor, Japanese Society of Mood Disorders
- Director, Japanese Society of Neuropsychopharmacology
- Director, Japanese Society of Clinical Neuropsychopharmacology
- Affiliated hospital
- Kansai Medical University Medical Center
- Website
- https://hp.kmu.ac.jp/takii/
- location
-
〒570-8507
10-15 Fumizono-cho, City of Moriguchi, Google Map Map
- Biography
-
- 1997
- Graduated from Kansai Medical University
- 1997
- Joined the Department of Psychiatry and Neurology, Kansai Medical University
- 2000
- Okura-kai Medical Corporation, Geisei Hospital
- 2002
- Assistant Professor, Kansai Medical University
- 2006
- Department of Psychiatry and Neurology, University of Bologna
- 2008
- Assistant Professor, Kansai Medical University
- 2009
- Associate Professor, Kansai Medical University
- 2014
- Associate Professor, Kansai Medical University
- 2019
- Chair, Department of Psychiatry and Neurology, Kansai Medical University Hospital
- 2024
- Professor, Kansai Medical University
- paper
-
- Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacol Rep. 2024;44:267-271.
- Characteristics of persistent depression in the long-term: Randomized controlled trial and two-year observational study. Heliyon. 2023;9:e20917.
- "Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study. " Psychiatry Clin Neurosci. 2023.
- "Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial." Psychiatry Clin Neurosci. 2023.
- "The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials." J Affect Disord. 2023.
- Appropriate duration of antidepressant medications for prevention of depressive relapse and the impact of life stage. Mol Psychiatry. 2023.
- Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study. Eur J Clin Pharmacol. 2023.
- "Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis. " International Journal of Molecular Sciences. 2023;24:12199.
- Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. J Affect Disord. 2022;314:27-33.
- "Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways." Journal of Molecular Sciences. 2022;23:3873.
- "Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis." Mol Psychiatry. 2021;26:118-133.
- Medical Education Panel of the Japanese Society of Clinical N. Pharmacological management of depression: Japanese expert consensus. J Affect Disord. 2020;266:626-632.
- Medical Education Panel of the Japanese Society of Clinical N. Pharmacological management of bipolar disorder: Japanese expert consensus. Bipolar Disord. 2020.
- Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. J Psychiatr Res. 2017;89:97-104.
- book
-
- Clinical Practice Guideline for Depression (Provisional Title), Japanese Society of Mood Disorders Publisher: Igaku-Shoin (planned) Publication date: 2025 (TBD) Masaki Kato – Executive Director (Responsible Officer)
- Practice Guidelines for Bipolar Disorder by the JSMD (Japanese Society of Mood Disorders). 633-645. Psychiatry Clin Neurosci. 2024;78 Kato T, Ogasawara K, Motomura K, Kato M, et al
- Chapter 2. Manic Episode Clinical Practice Guideline for Bipolar Disorder (Bipolar Disorder 2023), Japanese Society of Mood Disorders Igaku-Shoin, 2023; Vol. 1, No. 1, pp. 31–59. Authors: Masaki Kato, Iga, Tajika, Hori, Ogata, Koshikawa
- Bipolar Disorder: Depressive State; Current Therapeutic Guidelines – This Is How I Treat (2023 Edition) Igaku-Shoin, 2023; pp. 1043–1044. Author: Masaki Kato
- Chapter 2. Bipolar Disorder: What Is and Is Not Evidence-Based — Bipolar Disorder: What You Wanted to Know! Expert Consensus on Psychopharmacotherapy Shinko Igaku Shuppansha, 2023; Vol. 1, pp. 112–128. Author: Masaki Kato [et al.]
- Pharmacotherapy: Section 1. Antidepressants. Textbook of Clinical Neuropsychopharmacology for Specialists Edited by the Board of Specialists, Japanese Society of Clinical Neuropsychopharmacology Seiwa Shoten, 2022. Author: Masaki Kato
- Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia" :266-324 Neuropsychopharmacol Rep 2021 Sep;41(3) 2021年 Ishigooka J, Iwata N, Kusumi I,et al
- Chapter 5. Appropriate Use of Basic Psychotropic and Neurological Medications: How to Choose SSRI, SNRI, NaSSA, or SRIM for Depression? Monthly YAKUJI, May Special Issue, Vol. 63, No. 7, 2021; pp. 224–232. Jiho, Inc. Author: Masaki Kato